Cartesian Therapeutics completes automatic conversion of Series B Preferred Stock; 23.9M common shares outstanding

Cartesian Therapeutics, Inc.

Stockholders at Sept 20 special meeting approved issuance of common shares from Series B Preferred Stock conversion.
Automatic conversion of all Series B Non-Voting Convertible Preferred Stock completed on Sept 25, 2024.
Following conversion, there are 23,893,525 shares of common stock issued and outstanding.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.